Research progress on common adverse events caused by targeted therapy for colorectal cancer (Review)
| Autor: | Chenyan Fang, Dehou Deng, Bo Zhang, Liang Xia |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Bevacizumab Colorectal cancer medicine.medical_treatment Targeted therapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Regorafenib medicine Panitumumab Adverse effect Cetuximab business.industry medicine.disease Vascular endothelial growth factor 030104 developmental biology chemistry 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Oncology Letters. |
| ISSN: | 1792-1082 1792-1074 |
| Popis: | As targeted drug therapy is increasingly applied in the treatment of colon cancer, understanding and managing the adverse reactions of patients is becoming increasingly important. The present review examines the mechanisms of and adverse reactions to the most commonly used targeted drugs for colon cancer, and discusses methods of coping with these adverse reactions. Approved targeted drugs for metastatic colon cancer include monoclonal antibodies targeting vascular endothelial growth factor (VEGF), including bevacizumab, ziv-aflibercept and regorafenib, and monoclonal antibodies targeting epithelial growth factor receptor (EGFR), including cetuximab and panitumumab. The present review assesses the major adverse effects of these drugs and methods of dealing with reactions to them. VEGF inhibitors primarily result in cardiovascular and kidney problems. Meanwhile, EGFR receptor inhibitors are frequently reported to cause rashes, diarrhea and hypertension, and are reviewed from the point of view of resulting electrolyte disturbances. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|